1-6 of 6
Steven O’Day
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial

Espen B. Ellingsen, Steven O'Day, Artur Mezheyeuski, Agnieszka Gromadka, Trevor Clancy, Timothy S. Kristedja, Mohammed Milhem, Yousef Zakharia
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3026–3036.
https://doi.org/10.1158/1078-0432.CCR-23-0416
Published: 15 August 2023
View article titled, Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
Open the PDF for Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

Georgina V. Long, Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino, Steven O'Day, Victoria Atkinson, Jonathan S. Cebon, Michael P. Brown, Stéphane Dalle, Andrew G. Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5280–5288.
https://doi.org/10.1158/1078-0432.CCR-21-0793
Published: 01 October 2021
View article titled, Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Open the PDF for Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules in another window
Includes: Supplementary data
Journal Articles

Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

Katherine L. Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, Joel Greshock, Richard Letrero, Kurt D'Andrea, Steven O'Day, Jeffrey R. Infante, Gerald S. Falchook, Hendrik-Tobias Arkenau, Michael Millward, Michael P. Brown, Anna Pavlick, Michael A. Davies, Bo Ma, Robert Gagnon, Martin Curtis, Peter F. Lebowitz, Richard Kefford, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4868–4878.
https://doi.org/10.1158/1078-0432.CCR-13-0827
Published: 02 September 2013
View article titled, Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Open the PDF for Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

Caroline Robert, Dirk Schadendorf, Marianne Messina, F. Stephen Hodi, Steven O'Day
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2232–2239.
https://doi.org/10.1158/1078-0432.CCR-12-3080
Published: 15 April 2013
View article titled, Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
Open the PDF for Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control in another window
Journal Articles

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O'Day, Jeffrey S. Weber, Omid Hamid, Celeste Lebbé, Michele Maio, Michael Binder, Oliver Bohnsack, Geoffrey Nichol, Rachel Humphrey, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7412–7420.
https://doi.org/10.1158/1078-0432.CCR-09-1624
Published: 30 November 2009
View article titled, Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Open the PDF for Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Adjuvant Therapy with Anti-B4-blocked Ricin after Autologous Bone Marrow Transplantation for Patients with Relapsed B-Cell Non-Hodgkin’s Lymphoma

Michael L. Grossbard, Pratik S. Multani, Arnold S. Freedman, Steven O’Day, John G. Gribben, Catherine Rhuda, Donna Neuberg, Lee M. Nadler
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2392–2398.
Published: 01 September 1999
View article titled, A Phase II Study of Adjuvant Therapy with Anti-B4-blocked Ricin after Autologous Bone Marrow Transplantation for Patients with Relapsed B-Cell Non-Hodgkin’s Lymphoma
Open the PDF for A Phase II Study of Adjuvant Therapy with Anti-B4-blocked Ricin after Autologous Bone Marrow Transplantation for Patients with Relapsed B-Cell Non-Hodgkin’s Lymphoma in another window